ETF Managers Group’s Cue Biopharma CUE Stock Holding History

ETF Managers Group’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$48.3K	Buy	+451	New	+$43K	﹤0.01%	660
2022 Q4	–	Sell	-348	Closed	-$23K	–	559
2022 Q3	$23K	Sell	348 -25	-7%	-$2.15K	﹤0.01%	686
2022 Q2	$32K	Buy	373 +52	+16%	+$6.08K	﹤0.01%	727
2022 Q1	$45K	Buy	321 +1	+0.3%	+$212	﹤0.01%	660
2021 Q4	$109K	Sell	320 -44	-12%	-$17K	﹤0.01%	631
2021 Q3	$155K	Buy	364 +55	+18%	+$19.2K	﹤0.01%	622
2021 Q2	$112K	Hold	309	–	–	﹤0.01%	620
2021 Q1	$107K	Sell	309 -182	-37%	-$74.9K	﹤0.01%	634
2020 Q4	$190K	Sell	491 -60	-11%	-$24K	﹤0.01%	576
2020 Q3	$255K	Buy	551 +281	+104%	+$162K	0.01%	544
2020 Q2	$189K	Buy	+270	New	+$196K	0.01%	560

Other funds holding CUE

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ETF Managers Group's CUE Position: Q1 2023 in Review

ETF Managers Group opened a new position in Cue Biopharma (CUE) in Q1 2023: 451 shares worth $48.3K. The stake represents ﹤0.01% of the portfolio and ranks #660 among its holdings. This is a return to the name: ETF Managers Group previously reported a position in CUE as recently as Q3 2022.

ETF Managers Group first reported a position in CUE in Q2 2020 and has held it in 11 quarters since. The position peaked at $255K in Q3 2020. 63 funds tracked by Wall St. Rank hold CUE as of Q1 2023.

ETF Managers Group held 451 shares of Cue Biopharma worth $48.3K as of Q1 2023.
Cue Biopharma was a new ETF Managers Group position in Q1 2023.
Cue Biopharma made up ﹤0.01% of ETF Managers Group's portfolio in Q1 2023, its #660 holding.
ETF Managers Group first reported a position in Cue Biopharma in Q2 2020 and has held it in 11 quarters since.
ETF Managers Group's Cue Biopharma position peaked at $255K in Q3 2020.
63 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.